None listed
Conditions
Brief summary
The ACTIVate Study is a joint project between the University of South Australia, the University of Newcastle, the University of Adelaide, Flinders University and the University of Illinois. Our aim is to investigate the effect of different lifestyle patterns on brain function in older adults. Specifically, we're interested in activity and diet compositions, and how these might influence our risk of developing dementia. Four hundred and fifty participants will be recruited in Adelaide and Newcastle and followed over 3 years to monitor changes in lifestyle factors, brain structure and function, and overall health. From the information we collect we will develop a tool that will enable older adults to tailor their ‘best day’ of activity and diet compositions to reduce dementia risk.
Interventions
Participants aged 60-70 years will be followed for 3 years to monitor changes in cognitive function. Data will be collected at baseline, 18 months and 36 months at sites in Adelaide and Newcastle. At baseline and 36month visits, participants will attend 3 sessions in Adelaide and 2 sessions in Newcastle.
At Session 1, Adelaide participants will arrive fasted for 12 hours from all food and beverages, excluding water and regular medication. Participants will provide informed consent and undergo
Participants aged 60-70 years will be followed for 3 years to monitor changes in cognitive function. Data will be collected at baseline, 18 months and 36 months at sites in Adelaide and Newcastle. At baseline and 36month visits, participants will attend 3 sessions in Adelaide and 2 sessions in Newcastle. At Session 1, Adelaide participants will arrive fasted for 12 hours from all food and beverages, excluding water and regular medication. Participants will provide informed consent and undergo anthropometric measures. A venous blood sample will be collected to measure BDNF, lipids and glucose in the Adelaide cohort. Saliva samples will be collected in both Adelaide and Newcastle to measure APOE genotype. Participants will then complete diet and lifestyle questionnaires and undergo 90 minutes of cognitive assessments. Participants will then be given an activity monitor to wear for 7 days. Between Session 1 and Session 2 participants will be contacted by phone to complete the Multimedia Activity Recall (MARCA) to validate activity monitor data. At Session 2, participants will undergo an MRI brain scan to measure brain structure, connectivity and white matter hyper-intensities. EEG will then be recorded while participants complete a 60-minute executive function task-switching paradigm. Participants in Adelaide will then complete a 2-hour TMS-EEG protocol to measure brain plasticity and connectivity. Participants in Newcastle will undergo optical imaging to measure cerebral artery elasticity. At Session 3 (Adelaide only) participants will complete another TMS-EEG session, identical to that administered in the Session 2. Only Session 1 will take place at 18 months.
Sponsors
Dr Ashleigh Smith
Eligibility
Sex/Gender
All
Age
60 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
Community-dwelling adults aged 60-70 years who are fluent in the English language and meet safety criteria for TMS and MRI
Exclusion criteria
Overall study exclusion criteria: • Blindness, colour blindness or vision difficulties that cannot be corrected by glasses or contact lenses • Major neurological or psychiatric diagnosis • Known intellectual disability • Major physical disability • Previous head trauma resulting in a loss of consciousness of more than 5 minutes • Current or previous alcohol or substance abuse or dependence • Recreational drug use in the last 3 months • Previous stroke or diagnosed transient ischemic attack • Cancer treatment in the past 5 years • Unable to undergo TMS or MRI assessments (detailed below), or unable to wear an EEG cap • Scores below the mild cognitive impairment (MCI) cut-off on the Telephone Montreal Cognitive Assessment (T-MoCA) or a current diagnosis of dementia TMS exclusion criteria: • Current medications targeting the central nervous system (including anticonvulsants and antidepressants) • History of epilepsy, convulsions or seizures • History of severe head trauma followed by loss of consciousness • Presence of metal in the brain or skull (excluding titanium) or a neurostimulator implant • Cochlear implants • Presence of pacemaker, intracardiac lines, implants or metals • Presence of a medication infusion device • History of surgical procedures to the spinal cord or any spinal or ventricular derivations MRI exclusion criteria: • Presence of a pacemaker • Presence of metal implants, including aneurysm clips; brain shunt tubes; artificial heart valves; intravascular coils, filters or stents; vascular clips or wires; neurological implants (neurotransmitters or biostimulators); metal pins, plates, rods or screws • Cochlear or other ear implants • Presence of metal fragments or foreign objects in the eyes, skin or body, including; metallic fragments near the eyes or spinal cord; • Any other form of implant (excluding dental fillings)
Outcome results
None listed